These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
398 related articles for article (PubMed ID: 38844984)
1. Effects of super-enhancers in cancer metastasis: mechanisms and therapeutic targets. Liu S; Dai W; Jin B; Jiang F; Huang H; Hou W; Lan J; Jin Y; Peng W; Pan J Mol Cancer; 2024 Jun; 23(1):122. PubMed ID: 38844984 [TBL] [Abstract][Full Text] [Related]
2. EphA2 super-enhancer promotes tumor progression by recruiting FOSL2 and TCF7L2 to activate the target gene EphA2. Cui S; Wu Q; Liu M; Su M; Liu S; Shao L; Han X; He H Cell Death Dis; 2021 Mar; 12(3):264. PubMed ID: 33712565 [TBL] [Abstract][Full Text] [Related]
3. Oncogenic super-enhancer formation in tumorigenesis and its molecular mechanisms. Jia Q; Chen S; Tan Y; Li Y; Tang F Exp Mol Med; 2020 May; 52(5):713-723. PubMed ID: 32382065 [TBL] [Abstract][Full Text] [Related]
4. [Research progress of super enhancer in cancer]. Wu ZQ; Mi ZY Yi Chuan; 2019 Jan; 41(1):41-51. PubMed ID: 30686784 [TBL] [Abstract][Full Text] [Related]
5. The Emerging Role of Super-enhancers as Therapeutic Targets in The Digestive System Tumors. Li XP; Qu J; Teng XQ; Zhuang HH; Dai YH; Yang Z; Qu Q Int J Biol Sci; 2023; 19(4):1036-1048. PubMed ID: 36923930 [TBL] [Abstract][Full Text] [Related]
6. The emerging role of super enhancer-derived noncoding RNAs in human cancer. Wang Y; Nie H; He X; Liao Z; Zhou Y; Zhou J; Ou C Theranostics; 2020; 10(24):11049-11062. PubMed ID: 33042269 [TBL] [Abstract][Full Text] [Related]
7. Super-enhancers: Implications in gastric cancer. Huang Y; Huo Y; Huang L; Zhang L; Zheng Y; Zhang N; Yang M Mutat Res Rev Mutat Res; 2024; 793():108489. PubMed ID: 38355091 [TBL] [Abstract][Full Text] [Related]
8. Super-enhancers complexes zoom in transcription in cancer. Wang M; Chen Q; Wang S; Xie H; Liu J; Huang R; Xiang Y; Jiang Y; Tian D; Bian E J Exp Clin Cancer Res; 2023 Jul; 42(1):183. PubMed ID: 37501079 [TBL] [Abstract][Full Text] [Related]
9. Oncogenic super-enhancers in cancer: mechanisms and therapeutic targets. Bacabac M; Xu W Cancer Metastasis Rev; 2023 Jun; 42(2):471-480. PubMed ID: 37059907 [TBL] [Abstract][Full Text] [Related]
10. Deciphering molecular mechanisms of metastasis: novel insights into targets and therapeutics. Kalita B; Coumar MS Cell Oncol (Dordr); 2021 Aug; 44(4):751-775. PubMed ID: 33914273 [TBL] [Abstract][Full Text] [Related]
11. Super-enhancers and novel therapeutic targets in colorectal cancer. Liu Q; Guo L; Lou Z; Xiang X; Shao J Cell Death Dis; 2022 Mar; 13(3):228. PubMed ID: 35277481 [TBL] [Abstract][Full Text] [Related]
12. Super enhancer lncRNAs: a novel hallmark in cancer. Song P; Han R; Yang F Cell Commun Signal; 2024 Apr; 22(1):207. PubMed ID: 38566153 [TBL] [Abstract][Full Text] [Related]
13. Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma. Li M; Han Y; Wang C; Kang W; Jiang W; Zhang L; Tang Y J Exp Clin Cancer Res; 2022 Oct; 41(1):311. PubMed ID: 36273157 [TBL] [Abstract][Full Text] [Related]
14. Epigenetic Modifiers in Cancer Metastasis. Hu D; Zhao T; Xu C; Pan X; Zhou Z; Wang S Biomolecules; 2024 Jul; 14(8):. PubMed ID: 39199304 [TBL] [Abstract][Full Text] [Related]
15. Super-enhancers in cancer. Thandapani P Pharmacol Ther; 2019 Jul; 199():129-138. PubMed ID: 30885876 [TBL] [Abstract][Full Text] [Related]
16. FOSL1 promotes metastasis of head and neck squamous cell carcinoma through super-enhancer-driven transcription program. Zhang M; Hoyle RG; Ma Z; Sun B; Cai W; Cai H; Xie N; Zhang Y; Hou J; Liu X; Chen D; Kellogg GE; Harada H; Sun Y; Wang C; Li J Mol Ther; 2021 Aug; 29(8):2583-2600. PubMed ID: 33794365 [TBL] [Abstract][Full Text] [Related]
17. Multifaceted Roles of DNA Methylation in Neoplastic Transformation, from Tumor Suppressors to EMT and Metastasis. Casalino L; Verde P Genes (Basel); 2020 Aug; 11(8):. PubMed ID: 32806509 [TBL] [Abstract][Full Text] [Related]
18. Super enhancers as master gene regulators in the pathogenesis of hematologic malignancies. Dębek S; Juszczyński P Biochim Biophys Acta Rev Cancer; 2022 Mar; 1877(2):188697. PubMed ID: 35150791 [TBL] [Abstract][Full Text] [Related]
19. Targeted therapy of epigenomic regulatory mechanisms controlling the epithelial to mesenchymal transition during tumor progression. Mishra VK; Johnsen SA Cell Tissue Res; 2014 Jun; 356(3):617-30. PubMed ID: 24833164 [TBL] [Abstract][Full Text] [Related]
20. Disruption of super-enhancer-driven tumor suppressor gene RCAN1.4 expression promotes the malignancy of breast carcinoma. Deng R; Huang JH; Wang Y; Zhou LH; Wang ZF; Hu BX; Chen YH; Yang D; Mai J; Li ZL; Zhang HL; Huang Y; Peng XD; Feng GK; Zhu XF; Tang J Mol Cancer; 2020 Aug; 19(1):122. PubMed ID: 32771023 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]